Lumasiran and vutrisiran were designed for liver-targeted gene silencing of hydroxyacid oxidase 1 (HAO1) in primary hyperoxaluria type 1 (PH1),268 and TTR in hATTR amyloidosis,269 respectively (Figure 3). Here, HAO1 is linked to primary hyperoxaluria type 1.